AbbVie Reports Three-Year VIALE-A Data for Venclexta in Acute Myeloid Leukemia

AbbVie today presented three-year overall survival data from the Phase 3 VIALE-A trial evaluating Venclexta (venetoclax) plus azacitidine in patients with newly diagnosed acute myeloid leukemia who were ineligible for intensive chemotherapy. The data showed that the overall survival benefit of Venclexta was maintained at three years, with 25% of patients alive at three years compared to 12% in the placebo arm.